Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical research study is to find out if Caphosol® (calcium phosphate) mouthwash is more effective than a baking soda solution at preventing and treating mucositis, in patients with sarcoma who are to be treated with chemotherapy. The safety of this drug will also be studied. Researchers also want to learn about the way calcium phosphate may affect mucous membranes.

The goal of this clinical research study is to see if Caphosol® (calcium phosphate) mouthwash is better than baking soda solution in patients with sarcoma who are to be treated with chemotherapy . Caphosol will also be studied to see if it lessens the incidence and severity of oral mucositis (painful sores in the mouth).


Clinical Trial Description

Chemotherapy and radiation therapy can hurt normal cells in the gastrointestinal tract (which includes the mouth and intestines). When this happens, it can cause mucositis (inflammation of the lining of the mouth, throat, and intestines). Researchers want to compare the effects of calcium phosphate and baking soda on patients who are at risk for mucositis.

The Study Drugs:

Caphosol (calcium phosphate) is a saliva-like liquid that is designed to replace the chemical and pH (acid) balance in the mouth. It is used as a mouth rinse to moisten, lubricate, and clean the mouth, including the lining of the mouth, tongue, and throat. It is also used to loosen thick mucous and help prevent the mucous membranes from sticking together.

Baking soda is used as the standard of care for preventing and treating mucositis.

Study Groups:

If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to receive either calcium phosphate mouth rinse or the baking soda mouth rinse during the study. There is an equal chance of being assigned to either group.

You will use the mouth rinse 5 times every day. The study staff will explain how to mix and rinse with it.

Calcium phosphate should be stored at room temperature and should not be refrigerated. If you are on a low sodium diet, you should check with your doctor before using calcium phosphate.

Baseline Tests:

The following tests and procedures will be performed before you receive your first dose of chemotherapy:

- Blood (about 3 teaspoons) will be drawn for routine tests.

- The mucous membranes in your mouth will be checked.

- You will be asked to complete a questionnaire (about 15 minutes) on how you feel.

- You will be given a diary before you start each cycle to record if you have any mouth pain.

Study Tests:

You will need to come to MD Anderson on around Days 10, 12, and 14 (depending on the status of the mucositis) of each chemotherapy cycle. During these clinic visits, the following tests and procedures may be performed:

- You will have a physical exam, including measurement of your vital signs and weight.

- Blood (about 3 teaspoons) will be drawn for routine tests.

- The mucous membranes in your mouth will be checked. Also, you may have your mouth and throat photographed.

- You will be asked to complete the questionnaire on how you feel.

- When possible, the optical imaging procedures will also be performed on these days.

Length of Study and Reasons for Leaving the Study Early:

You will take part in this study for up to 18 weeks (4 to 5 months). You will be taken off study if you experience intolerable side effects.

End of Study Visit:

You will also have an end of study visit after you complete 6 cycles of study drug, if you are taken off study for any reason, or if you choose to leave the study. During this visit, the following tests and procedures will be performed:

- You will have a physical exam, including measurement of your vital signs and weight.

- Blood (about 3 teaspoons) will be drawn for routine tests.

- The mucous membranes in your mouth will be checked.

- You will be asked to complete the questionnaire on how you feel.

- You will receive a phone call from the nurse after you last dose of study drug to follow up on any side effects.

This is an investigational study. Caphosol (calcium phosphate) is FDA approved and commercially available for use in preventing and treating mucositis, and for relief of dry mouth during high dose chemotherapy or radiation treatment.

Up to 30 patients will take part in this study. All will be enrolled at M. D Anderson. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00965172
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Completed
Phase Phase 2
Start date April 2010
Completion date February 2012

See also
  Status Clinical Trial Phase
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Recruiting NCT04457258 - 68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma Early Phase 1
Completed NCT04474678 - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") N/A
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT04535713 - GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma Phase 2
Completed NCT03521531 - Burden and Medical Care of Sarcoma in Germany
Completed NCT02496520 - Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults Phase 1/Phase 2
Terminated NCT02054104 - Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Phase 1/Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Completed NCT04052334 - Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma Phase 1
Completed NCT01593748 - A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Phase 2
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Recruiting NCT04367779 - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Completed NCT01879085 - Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Phase 1/Phase 2
Recruiting NCT04553692 - Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers Phase 1
Completed NCT01209598 - PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Phase 2
Completed NCT04553471 - Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers N/A
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2